US Edition
News from curetoday.com
We’ve assigned a media bias rating of unknown to curetoday.com. You can read more about our methodology here.
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top curetoday.com News
United States · United StatesFDA clears expanded use of AKEEGA as the first PARP-based precision combo for BRCA2-mutated mCSPC, cutting progression or death 54 percent and delaying symptoms 59 percent in Phase 3.See the Story
Johnson & Johnson (NYSE: JNJ) Gets FDA OK; AKEEGA Delays BRCA2 mCSPC Progress 59 Percent
61% Center coverage: 36 sources
Eli Lilly · IndianapolisIn addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% for ibrutinib in the intent-to-treat (ITT) populationSee the Story
Lilly's Jaypirca (Pirtobrutinib) Met Its Primary Endpoint in First-of-Its-Kind, Head-to-Head Phase 3 Study versus Imbruvica (Ibrutinib)
65% Center coverage: 26 sources
Breast Cancer(MedPage Today) -- SAN ANTONIO -- Menopausal hormone therapy (MHT) did not increase breast cancer risk in women with BRCA mutations, according to a study reported here.
In fact, women who used estrogen-only MHT had a significantly lower risk...See the Story
No Increased Breast Cancer Risk With Menopausal Estrogen in BRCA Carriers
100% Center coverage: 1 sources
